OliX Pharmaceuticals, Inc announced a private placement to issue Series 3 Bearer Interest Unsecured Private Placement Convertible Bonds for gross proceeds of KRW 14,700,000,000 on March 20, 2024. The transaction will include participation from new investors KB Securities Co., Ltd. (in the fiduciary position of Funds 1 and 21) for KRW 1,000,000,000, NH Investment & Securities Co., Ltd. (in the fiduciary position of funds 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 25, 27, 28, 30) for KRW 1,950,000,000, Korea Investment & Securities Co., Ltd. (in the fiduciary position of Funds 3, 18, 19, 20, 22) for KRW 2,500,000,000, Standard Chartered Bank Korea Limited (in the fiduciary position of Funds 14 and 15) for KRW 1,000,000,000, Samsung Securities Co., Ltd. (in the fiduciary position of Funds 16 and 17) for KRW 500,000,000, The Korea Securities Finance Corporation (in the fiduciary position of Funds 23 and 24) for KRW 1,000,000,000, Mirae Asset Securities Co., Ltd. (in the fiduciary position of Funds 26, 29, 31 and 32) for KRW 550,000,000, Hana Investment Banking & Securities Inc. for KRW 2,000,000,000 and Orbit Bio-Healthcare New Technology Business Investment Fund for KRW 4,200,000,000. The transaction has been approved by the shareholders of the company and is expected to close on March 22, 2024.

The bonds are 100% convertible into 902,782 shares at a fixed conversion conversion price of KRW 16,283 from March 22, 2025 to February 22, 2029. The bonds bear zero coupon rate and 3.5% maturity rate and matures on March 22, 2029.